Investment Climate Podcast: Lorenzo Pessini of NOUS on Landing dsm-firmenich as a Strategic Lead and the Clinical Study That Closed the Round

In the latest episode of the Investment Climate Podcast, CEO and Founder of NOUS, Lorenzo Pessini, discusses the company's recent success in securing a €2.315M seed round led by dsm-firmenich Ventures. Pessini details how the company strategically pivoted their flagship ingredient, Koncentra, from a "caffeine alternative" to a botanical brain-wellbeing ingredient for energy, focus, and mood. The key to closing the round was a clinical study conducted jointly with dsm-firmenich, showcasing the importance of working closely with strategic partners in the industry.

Pessini also shares insights into the mechanics of clinical studies, the benefits of a B2B business model over B2C, and the importance of transparency and patience in building corporate partnerships. NOUS focuses on developing science-backed functional ingredients for food, beverage, and nutraceuticals, positioning itself as a player in the future of food technology by prioritizing scientifically-validated building blocks over consumer brands.